Pancreatic Cancer

Gayle S. Jameson, M.S.N, ACNP-BC, AOCN, is a trailblazer whose expertise and compassion have made a profound impact on oncology care.

Enclosed is the 2025 Quarter 1 – COA Patient Advocacy Network News Bulletin.

Eraglusib with gemcitabine and nab-paclitaxel achieved statistical significance in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

This is a joint nomination by Camille Moses and Dr. Estelamari Rodriguez.

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study.

Experts at Hackensack Meridian Jersey Shore University Medical Center have successfully treated their first patients using the TAMP™ therapy platform.

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient with pancreatic cancer.

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel treatment for the disease.

The phase 2 TEDOPaM trial evaluating patients with advanced or metastatic pancreatic ductal adenocarcinoma met its primary end point.

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support.

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

The recent American Cancer Society’s Cancer Statistics, 2025 report was released revealing a sobering trend for pancreatic cancer.

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic cancer.

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.

Patients with locally advanced pancreatic cancer demonstrated a two-month difference in survival with tumor-treating fields versus chemotherapy.

Before I underwent surgery to remove tumors on several organs, I was told it was the only way to determine what cancer I had.

From the deaths of actor Paul Teal and Chicago Bulls player Bob Love to a contestant on “Jeopardy!” revealing his colon cancer diagnosis, here’s what’s happening in the oncology space this week.

From producer Quincy Jones’ death from pancreatic cancer to an inspiring moment between The Rock and a fan at a store, here’s what’s happening in the cancer space this week.

Ponsegromab helped patients with cachexia and elevated GDF-15 levels gain weight, increase activity and improve cachexia symptoms, with manageable safety.

From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.

Patients with oligometastatic pancreatic cancer showed better progression-free survival after receiving metastasis-directed therapy with chemotherapy.

Researchers are enrolling patients in a trial of ELI-00 7P — a vaccine to treat KRAS-mutant cancer.